The 10 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 18.00, with a high estimate of 26.00 and a low estimate of 13.00. The median estimate represents a +95.02% increase from the last price of 9.23.
The current consensus among 13 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.21
Reporting Date Nov 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.